IL2 and metastatic melanoma: Interleukin-2, a potent T cell activator, is approved for the treatment of renal cell carcinoma and metastatic melanoma (64, 65), where high-dose regimens produce significant clinical responses (66) but are hindered by severe toxicity (67).